Selecta Biosciences, Inc. (NASDAQ:SELB) Q1 2021 Earnings Conference Call May 5, 2022 8:30 AM ET
Company Participants
Carsten Brunn - President & Chief Executive Officer
Kevin Tan - Chief Financial Officer
Peter Traber - Chief Medical Officer
Kei Kishimoto - Chief Scientific Officer
Conference Call Participants
John Newman - Canaccord
Kristen Kluska - Cantor Fitzgerald
Yun Zhong - BTIG
Raju Prasad - William Blair
Uy Ear - Mizuho
Boobalan Pachaiyappan - HC Wainwright
Chang Liu - Needham
Operator
00:05 Good morning and welcome to the Selecta Biosciences First Quarter 2022 Financial Results and Corporate Update Conference Call. Currently, all participants are in a listen-only mode. This call is being webcast live on the Investors and Media section of Selecta's website at www.selectabio.com, and it is being recorded.
00:27 For opening remarks, I would like to introduce Kevin Tan, Chief Financial Officer of Selecta. Please go ahead.
Kevin Tan
00:34 Thank you and good morning. Welcome to our first quarter 2022 financial results and corporate update conference call. The press release reporting our financial results is available in the Investors and Media section of Selecta's website, www.selectabio.com and our quarterly report on Form 10-Q for the quarter ended March 31, 2022 which will be filed today with the Securities and Exchange Commission or SEC.
01:04 Joining me today are Carsten Brunn, President and Chief Executive Officer; Peter Traber, Chief Medical Officer; and Kei Kishimoto Chief Scientific Officer.
01:16 During today's call we will be making certain forward-looking statements, including without limitation, statements about the potential safety, efficacy and regulatory and clinical progress of our product candidates, financial projections and our future expectations, plans, partnerships and prospects. These statements are subject to various risks that are described in the filings made with the SEC, including our quarterly report on Form 10-Q. You are cautioned not to place undue reliance on these forward-looking statements which speak only as of today, May 5, 2022 and Selecta disclaims any obligation to update such statements, even if management's views change.
02:04 I would now like to turn the call over to Carsten. Carsten?
Carsten Brunn
02:09 Good morning. I appreciate everyone taking the time to join us today. Despite geopolitical turbulence, max economic volatility and sector specific headwinds, we believe Selecta’s proactive approach to managing risk, which included opening additional SEL-212 clinical trial sites in the US in the face of heightened geopolitical instability, prioritizing our product portfolio to manage our resources and raising additional capital ensures that Selecta can build on the exciting progress made in 2021 and realize the full potential of our leading precision immune tolerance platform.